Comparison between intravitreal bevacizumab alone or in combination with subthreshold diode micro pulse (SDM) laser in diabetic macular edema / (Record no. 170582)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 08014namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033424.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250203b2024 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 617.735 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 617.735 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.11.24.Ph.D.2024.Ho,C |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Hossam El Din Farag Abdel Halim Abd Allah, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Comparison between intravitreal bevacizumab alone or in combination with subthreshold diode micro pulse (SDM) laser in diabetic macular edema / |
| Statement of responsibility, etc. | by Hossam El Din Farag Abdel Halim Abd Allah ; Supervision of Prof. Dr. Hany Salah El Din Mahmoud Hamza, Prof. Dr. Ahmed Mohamed Ali Abdelbaki, Prof. Dr. Shaymaa Hassan Salah. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | مقارنة بين حقن مادة البيفاسيزوماب داخل الجسم الزجاجي بمفرده أو مع ديود ليزر ميكرو النبضة دون الحد في ارتشاح الماقولة السكري / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 133 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 96-133. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Purpose: Comparison between intravitreal Bevacizumab monotherapy versus combined intravitreal injection with subthreshold diode micropulse (SDM) laser in treatment of center involving diabetic macular edema regarding the number of needed reinjections during the follow up period. Changes in the CFT and BCVA were secondary objectives to our study. Also, OCTA vascular parameters changes were evaluated in the combined group. <br/>Design: Prospective comparative randomized interventional clinical study.<br/>Methods: This study included 70 eyes with center involving DME divided into 2 groups: the intravitreal injection monotherapy group included 35 eyes and the combined (injection and SDML) group included 35 eyes. The patients’ age ranged from 51 to 72 years in the injection monotherapy group and from 49 to 71 years in the combined group. Both groups received 3 initial intravitreal Bevacizumab injections one month apart. Then, only the combined group received one session of 810 nm subthreshold diode micropulse laser (OcuLight SLx; Iridex Corporation, Mountain View, CA, USA) 2 weeks after the 3rd intravitreal injection. Both groups were followed up for 6 months. SD OCT (RTVue XR 100 Avanti instrument (Optovue Inc, Fremont, CA, USA) was used to evaluate the central foveal thickness and BCVA was evaluated at monthly follow up visits. OCTA was done using the same device to evaluate the vascular changes in eyes in the combined group at baseline, 3 months, and 6 months after the laser session.<br/>Results: <br/>The average number of needed reinjections in the injection only group was 2.2±1.18 while in the combined group was 0.86±1.00 which was statistically significant (p value <0.001). The average CFT in the injection group was 317.31±41.25µm at 6 months and was 288.20 ±18.46µm in the combined group. The average logMAR BCVA improved from 0.97 ± 0.28 in the injection group at baseline to 0.46 ± 0.17 at 6 months while in the combined group, logMAR BCVA changed from 0.86 ± 0.26 to 0.34 ± 0.15 at the end of follow up. The average VD at SCP changed from 41.54±3.41 to 42.39±3.31 and 42.17±3.27 at baseline, 3 months, and 6 months respectively. The average VD at DCP changed from 41.48±3.27 to 42.09±3.25 and 42.10±3.12 at baseline, 3 months, and 6 months respectively. The average number of MAs decreased from 3.37±0.69 at baseline to 1.74±0.61 and 1.40±0.91 at 3 and 6 months.<br/>Conclusions:<br/>The average number of needed reinjections in the combined group was significantly lower than in the injection monotherapy group. There was a significant reduction in the CFT in both groups and the average CFT was significantly lower in the combined group at 6 months. BCVA significantly improved in both groups with statistically significant difference in the BCVA change between combined and injection monotherapy group. OCTA parameters in the SCP and DCP significantly improved at 3 months after SDML, and improvement was maintained up to 6 months follow up. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | إن ارتشاح الماقولة السكرى هو السبب الرئيس لضعف الابصار في مرضى السكر. ويعد حقن المواد الدوائية المضادة لعامل نمو بطانة الأوعية الدموية العلاج الأول لحالات ارتشاح الماقولة السكرى المتضمن لمركز الابصار. <br/>تم استبدال علاج الماقولة بالليزر بحقن هذه المواد الدوائية تجنبا للآثار الجانبية لليزر الا أن الاستحثاث الضوئي لخلايا الشبكية الصبغية الطلائية باستخدام أشكال الليزر دون حد الحرق قد أظهر نتائج واعدة في مختلف أمراض الشبكية بما فيها ارتشاح الماقولة السكري.<br/>إن ديود ليزر ميكرو النبضة دون الحد قد أظهر فاعلية في مختلف الدراسات في علاج ارتشاح الماقولة السكري سواء بديلا لحقن المواد الدوائية داخل الجسم الزجاجي في حالات الارتشاح البسيطة أو كمساعد للحقن داخل الجسم الزجاجي في الحلات المتوسطة والشديدة لارتشاح الماقولة السكري وذلك لتقليل عدد الحقن لتخفيف العبء الاقتصادي وكذلك الآثار الجانبية المحتملة للحقن وأخطرها الالتهاب الصديدي داخل العين.<br/>دراستنا الحالية تضمنت مرضى يعانون من ارتشاح الماقولة السكرى المتضمن لمركز الابصار وعلاجهم بثلاث حقنات أولية بالعلاج الدوائي (بيفاسيوماب) المضاد لمعامل نمو بطانة الأوعية الدموية وتم تقسيمهم الى مجموعتين: الأولى تم علاجهم بالحقن فقط أما الأخرى تم علاجها بجلسة ديود ليزر ميكرو النبضة إضافة الى الحقن. وخلال فترة المتابعة، احتاجت مجموعة المرضى الذين تم علاجهم بالحقن مع ديود ليزر ميكرو النبضة الى عدد حقنات أقل عن مجموعة المرضى الذين تم علاجهم بالحقن فقط. كلتا المجموعتين أظهرتا انخفاض في سمك الشبكية المركزي وتحسن في حدة الابصار خلال فترة المتابعة غير أن التغيرات كانت أكثر وضوحا في مجموعة الليزر. كذلك أدى استخدام ديود ليزر ميكرو النبضة الى تحسن في العوامل التشريحية خلال تصوير الأوعية الدموية المقطعي الضوئي في كلا من الضفيرة الشعيرية السطحية والعميقة. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Retinal diseases |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Diabetic macular edema |
| -- | subthreshold micropulse diode laser |
| -- | Anti-VEGF |
| -- | burden of injection |
| -- | Optical coherence tomography angiography |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hany Salah El Din Mahmoud Hamza |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ahmed Mohamed Ali Abdelbaki |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shaymaa Hassan Salah |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Hany Salah El Din Mahmoud Hamza |
| -- | Ahmed Mohamed Ali Abdelbaki |
| -- | Shaymaa Hassan Salah |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Ophthalmology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 03.02.2025 | 90353 | Cai01.11.24.Ph.D.2024.Ho,C | 01010110090353000 | 03.02.2025 | 03.02.2025 | Thesis |